Close

Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints

Go back to Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints

Stifel Downgrades Threshold Pharmaceuticals (THLD) to Hold

December 7, 2015 7:31 AM EST

Stifel downgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Buy to Hold after the company announced negative topline data from both of its Phase III trials for TH-302 in pancreatic cancer and sarcoma.

Analyst Thomas Shrader commented, "Despite very positive phase II data, the... More

Threshold Pharma (THLD) Says Evofosfamide Studies Did Not Meet Primary Endpoints

December 7, 2015 6:18 AM EST

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany.

In the Phase 3 MAESTRO study, patients with previously untreated, locally advanced unresectable or metastatic pancreatic... More